ABOUT US
GROUND-BREAKING THERAPEUTICS

Scroll down to see more

About Laekna


Founded in 2016, Laekna is a clinical-stage global biotechnology company, dedicated to bringing ground-breaking therapies to cancer and liver fibrosis patients worldwide.


The company has two potential core products: LAE002 is an investigational highly selective adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The other Core Product LAE001 is an investigational potential first-in-class next-generation androgen synthesis inhibitor that simultaneously inhibits both CYP17A1 and CYP11B2 for the treatment of prostate cancer.


Laekna’s robust infrastructure has already enabled the rapid development of 14 innovative product candidates, including one pivotal clinical trial and another five clinical trials for our potential Core Products. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address urgent yet unmet global medical needs in the standard of care (SOC)-resistant cancers.


Laekna’s internal drug discovery primarily focuses on coordinating the human immune system to treat cancer and liver fibrosis.



Our Vision
Our Vision

We are committed to
becoming a globally leading innovative
biopharmaceutical
company
that can bring ground-breaking therapies
to cancer and liver fibrosis
patients worldwide.

Core Management Team
Milestones

Glossary & abbreviations

MCRPC: metastatic castration-resistant prostate cancer IND: investigational new drug MRCT: multi-regional clinical trial PROC: platinum-resistant ovarian cancer TNBC: triple negative breast cancer ActRIIA: activin receptor type IIA HR+/HER2- breast cancer: the most common type of breast cancer with overexpression of HR and without overexpression of HER2
Scientific Advisory Board
Peter ten Dijke
Back
  • Last :Peter ten Dijke
  • Next :Jeff Porter
Honors & Awards
  • 2022

    2022 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises

    2022 Pioneers: The Scientists

    KPMG China Future 50 - Biotech

  • 2021

    2021 China Corporate Social Responsibility Virtual Summit - CSR Good Practice

    2021 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises

    Pioneers to the Star 2021 Biomedicine Pioneer-10

    Frost & Sullivan 2021 Top 100 Technology Leaders - Top 50 Innovative Technology Leaders

  • 2020

    Top 20 Disruptive Technologies in Cancer

  • 2019

    China Healthcare Industry Investment and Financing Honor List: Top 20 Emerging Healthcare Companies

  • 2018

    2018 Insights Zhangjiang Top 100

More
  • 图片1
  • 图片2
  • 图片3
  • 图片4
    图片5
  • 图片6
  • 图片7
  • 图片8
  • 图片9
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation

News

Positions

Follow us on Linkedin